心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

慢性冠状动脉综合征增强型体外反搏治疗中国专家共识

2022-02-27 中国医师协会心血管内科医师分会 中国介入心脏病学杂志

冠状动脉疾病慢性冠状动脉综合征

目前,我国心血管病患病率仍处于上升阶段。心血管病现患人数约3.3亿,其中冠心病患者约1139万人。2019年《欧洲心脏病学会慢性冠状动脉综合征诊断和管理指南》根据临床表现将冠心病分为急性冠状动脉综合征

中文标题：

慢性冠状动脉综合征增强型体外反搏治疗中国专家共识

发布机构：

中国医师协会心血管内科医师分会

发布日期：

2022-02-27

简要介绍：

目前,我国心血管病患病率仍处于上升阶段。心血管病现患人数约3.3亿,其中冠心病患者约1139万人。2019年《欧洲心脏病学会慢性冠状动脉综合征诊断和管理指南》根据临床表现将冠心病分为急性冠状动脉综合征（acute coronary syndromes,ACS）和慢性冠状动脉综合征（chroniccoronary syndromes,CCS）,对不同临床类型的CCS提出了诊治和管理新理念,并将增强型体外反搏（enhanced external counter-pulsation,EECP）纳入治疗推荐。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=慢性冠状动脉综合征增强型体外反搏治疗中国专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=4f7641c0023e66ad, title=慢性冠状动脉综合征增强型体外反搏治疗中国专家共识, enTitle=, guiderFrom=中国介入心脏病学杂志, authorId=0, author=, summary=目前,我国心血管病患病率仍处于上升阶段。心血管病现患人数约3.3亿,其中冠心病患者约1139万人。2019年《欧洲心脏病学会慢性冠状动脉综合征诊断和管理指南》根据临床表现将冠心病分为急性冠状动脉综合征, cover=https://img.medsci.cn/2022310/1646892778204_5579292.png, journalId=0, articlesId=null, associationId=315, associationName=中国医师协会心血管内科医师分会, associationIntro=null, copyright=0, guiderPublishedTime=Sun Feb 27 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">目前,我国心血管病患病率仍处于上升阶段。心血管病现患人数约3.3亿,其中冠心病患者约1139万人</span><span style="color: #666666;">。2019年《欧洲心脏病学会慢性冠状动脉综合征诊断和管理指南》</span><span style="color: #666666;">根据临床表现将冠心病分为急性冠状动脉综合征（acute coronary syndromes,ACS）和慢性冠状动脉综合征（chroniccoronary syndromes,CCS）,对不同临床类型的CCS提出了诊治和管理新理念,并将增强型体外反搏（enhanced external counter-pulsation,EECP）纳入治疗推荐。&nbsp;</span></p>, tagList=[TagDto(tagId=1993, tagName=冠状动脉疾病), TagDto(tagId=75294, tagName=慢性冠状动脉综合征)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4419, appHits=91, showAppHits=0, pcHits=422, showPcHits=4328, likes=1, shares=41, comments=4, approvalStatus=1, publishedTime=Thu Mar 10 15:07:00 CST 2022, publishedTimeString=2022-02-27, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Mar 10 14:14:16 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Tue Jan 02 16:07:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=慢性冠状动脉综合征增强型体外反搏治疗中国专家共识.pdf)])
慢性冠状动脉综合征增强型体外反搏治疗中国专家共识.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1202202, encodeId=76781202202f9, content=学习一下！很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=106e6543620, createdName=ms1000000564332448, createdTime=Sun Mar 13 12:28:33 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201825, encodeId=9e0f120182502, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 23:02:33 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201761, encodeId=11031201e6174, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220311/279f05574ab640ea80a04c6da34c640b/4baa39c0318f4c978a2a76de5a86bac2.jpg, createdBy=79a26547966, createdName=ms2000002032972559, createdTime=Fri Mar 11 19:36:50 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201532, encodeId=034c1201532dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Thu Mar 10 21:34:02 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-03-13 ms1000000564332448

    学习一下！很棒

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1202202, encodeId=76781202202f9, content=学习一下！很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=106e6543620, createdName=ms1000000564332448, createdTime=Sun Mar 13 12:28:33 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201825, encodeId=9e0f120182502, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 23:02:33 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201761, encodeId=11031201e6174, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220311/279f05574ab640ea80a04c6da34c640b/4baa39c0318f4c978a2a76de5a86bac2.jpg, createdBy=79a26547966, createdName=ms2000002032972559, createdTime=Fri Mar 11 19:36:50 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201532, encodeId=034c1201532dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Thu Mar 10 21:34:02 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-03-11 ms7000001031705413

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1202202, encodeId=76781202202f9, content=学习一下！很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=106e6543620, createdName=ms1000000564332448, createdTime=Sun Mar 13 12:28:33 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201825, encodeId=9e0f120182502, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 23:02:33 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201761, encodeId=11031201e6174, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220311/279f05574ab640ea80a04c6da34c640b/4baa39c0318f4c978a2a76de5a86bac2.jpg, createdBy=79a26547966, createdName=ms2000002032972559, createdTime=Fri Mar 11 19:36:50 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201532, encodeId=034c1201532dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Thu Mar 10 21:34:02 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-03-11 ms2000002032972559

    学习一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1202202, encodeId=76781202202f9, content=学习一下！很棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=106e6543620, createdName=ms1000000564332448, createdTime=Sun Mar 13 12:28:33 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201825, encodeId=9e0f120182502, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 23:02:33 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201761, encodeId=11031201e6174, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220311/279f05574ab640ea80a04c6da34c640b/4baa39c0318f4c978a2a76de5a86bac2.jpg, createdBy=79a26547966, createdName=ms2000002032972559, createdTime=Fri Mar 11 19:36:50 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201532, encodeId=034c1201532dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Thu Mar 10 21:34:02 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-03-10 ms7000001031705413

    好

    0

相关指南

质子泵抑制剂在急性冠状动脉综合征患者中应用的争议与共识

北京医院心内科国家老年医学中心中国医学科学院老年医学研究院 · 2022-02-25

《穿支动脉粥样硬化病中国专家共识》解读

暂未更新 · 2021-12-20

冠状动脉综合征的无创成像：欧洲心血管成像协会和美国超声心动图协会与美国核心脏病学会、心血管计算机断层扫描协会和心血管磁共振协会合作的建议

欧洲协会心血管影像协会(EACVI,European Association of Cardiovascular Imaging) · 2021-12-10

冠状动脉MR血管成像临床应用专家共识（第一版）

中国医学装备协会磁共振应用专业委员会 · 2021-09-10

冠心病心脏康复基层指南(2020年)

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2021-02-03

血管内超声在冠状动脉疾病中应用的中国专家共识（2018）

中国心血管相关专家小组（统称） · 2018-05-20